<?xml version="1.0" encoding="UTF-8"?>
<PEPSResponse
    xsi:schemaLocation="ext/domain/pharmacy/peps/external/common/preencapsulation/vo/drug/check/response drugCheckSchemaOutput.xsd"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="ext/domain/pharmacy/peps/external/common/preencapsulation/vo/drug/check/response">
    <Header>
        <Time value="0845"/>
        <MServer namespace="VISTA" uci="text" ip="127.0.0.1"
            serverName="Server Name" stationNumber="45"/>
        <MUser userName="user" duz="88660079" jobNumber="1002"/>
        <PEPSVersion difIssueDate="20091002" difBuildVersion="6" difDbVersion="3.2"/>
    </Header>
    <Body>
        <drugCheck>
            <drugTherapyChecks>
                <drugTherapyCheck>
                    <id>107</id>
                    <source>FDB</source>
                    <interactedDrugList>
                        <drug orderNumber="Z;2;Prospect" ien="93268" gcnSeqNo="24538"/>
                        <drug orderNumber="Z;1;Prospect" ien="344" gcnSeqNo="58432"/>
                    </interactedDrugList>
                    <classification>Calcium Channel Blockers</classification>
                    <duplicateAllowance>0</duplicateAllowance>
                    <shortText>Use of DILTIAZEM HCL ORAL CAPSULE,SUSTAINED ACTION 240 MG and AMLODIPINE BESYLATE/ATORVASTATIN CALCIUM ORAL TABLET 2.5 MG-10 MG may represent a duplication in therapy based on their association to the therapeutic drug class Calcium Channel Blockers.</shortText>
                </drugTherapyCheck>
                <drugTherapyCheck>
                    <id>483</id>
                    <source>FDB</source>
                    <interactedDrugList>
                        <drug orderNumber="Z;2;Prospect" ien="93267" gcnSeqNo="16579"/>
                        <drug orderNumber="Z;1;Prospect" ien="344" gcnSeqNo="58432"/>
                    </interactedDrugList>
                    <classification>HMGCo-A Reductase Inhibitors</classification>
                    <duplicateAllowance>0</duplicateAllowance>
                    <shortText>Use of SIMVASTATIN ORAL TABLET 40 MG and AMLODIPINE BESYLATE/ATORVASTATIN CALCIUM ORAL TABLET 2.5 MG-10 MG may represent a duplication in therapy based on their association to the therapeutic drug class HMGCo-A Reductase Inhibitors.</shortText>
                </drugTherapyCheck>
            </drugTherapyChecks>
        </drugCheck>
    </Body>
